Free Trial
NASDAQ:GRCE

Grace Therapeutics Q4 2025 Earnings Report

Grace Therapeutics logo
$3.10 -0.02 (-0.64%)
As of 09/19/2025 04:00 PM Eastern

Grace Therapeutics EPS Results

Actual EPS
-$0.21
Consensus EPS
-$0.23
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Grace Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Grace Therapeutics Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
Monday, June 23, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Grace Therapeutics' Q2 2026 earnings is scheduled for Wednesday, November 12, 2025, with a conference call scheduled on Friday, November 14, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Grace Therapeutics Earnings Headlines

Why More Investors Are Using Family Trusts to Protect Their Wealth
For many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensuring wealth is passed on according to your wishes. Trusts may also provide shielding from creditors and lawsuits while offering potential tax advantages—especially with estate tax thresholds set to decrease in 2026. If you’re considering whether a family trust is right for you, speaking with a fiduciary financial advisor can help you decide the best path forward. We’ve created a free tool that matches you with vetted advisors in your area—each legally bound to act in your best interest.tc pixel
Wall Street Zen Upgrades Grace Therapeutics (NASDAQ:GRCE) to Hold
See More Grace Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Grace Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Grace Therapeutics and other key companies, straight to your email.

About Grace Therapeutics

Grace Therapeutics (NASDAQ:GRCE) (NASDAQ: GRCE) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for rare genetic diseases. By employing a proprietary platform that integrates advanced molecular biology and biologic engineering, the company focuses on identifying and optimizing gene-based and protein-based candidates designed to address well-defined genetic drivers of disease.

The company’s pipeline features multiple preclinical programs targeting lysosomal storage disorders and other inherited metabolic conditions. Through in-house capabilities and strategic partnerships with academic institutions and contract research organizations, Grace Therapeutics advances its candidates from target identification through lead optimization with the goal of accelerating entry into formal regulatory pathways.

Based in the United States, Grace Therapeutics serves a global patient community by collaborating with development partners worldwide. The management team combines experience in drug discovery, clinical development and regulatory affairs, positioning the company to navigate the complex requirements of orphan drug designation and clinical trial execution. With a focus on innovation and strategic alliances, Grace Therapeutics aims to deliver transformative treatments for patients affected by rare genetic disorders.

View Grace Therapeutics Profile

More Earnings Resources from MarketBeat